Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases in the United States. The company`s lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop antiviral Fc-conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and Coronavirus. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Website: cidara.com



Growth: Bad revenue growth rate -81.8%, there is slowdown compared to average historical growth rates 114.2%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is negative, -248.1%. On average the margin is decreasing steadily. Gross margin is high, +100.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.03 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -0.3% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 12 891.0% higher than minimum and 4.6% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -7.6x by EV / Sales multiple

Insiders: For the last 3 months insiders bought company shares on $100.1 mln (2.515% of cap.)

Key Financials (Download financials)

Ticker: CDTX
Share price, USD:  (-1.5%)61.85
year average price 21.55  


year start price 13.24 2024-07-27

min close price 10.17 2024-10-15

max close price 64.85 2025-07-23

current price 61.85 2025-07-26
Common stocks: 90 504 622

Dividend Yield:  0.0%
EV / Sales: 206.4x
Margin (EBITDA LTM / Revenue): -248.1%
Fundamental value created in LTM:
Market Cap ($m): 5 598
Net Debt ($m): -25
EV (Enterprise Value): 5 573
Price to Book: 48.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-06-26globenewswire.com

Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

2025-06-24globenewswire.com

Cidara Announces Pricing of Upsized Public Offering of Common Stock

2025-06-23globenewswire.com

Cidara Announces Proposed Public Offering of Common Stock

2025-05-25seekingalpha.com

Cidara Therapeutics: All Stars Aligning In Favor Of CD388

2025-05-10seekingalpha.com

Cidara Therapeutics, Inc. (CDTX) Q1 2025 Earnings Call Transcript

2025-05-05seekingalpha.com

Cidara Therapeutics: Strong Buy On Imminent Data Readout For Lead Flu Candidate

2025-03-21zacks.com

Wall Street Analysts Predict a 64.5% Upside in Cidara Therapeutics (CDTX): Here's What You Should Know

2025-03-06globenewswire.com

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

2025-02-18globenewswire.com

Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer

2024-12-03zacks.com

Cidara Therapeutics (CDTX) Just Flashed Golden Cross Signal: Do You Buy?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CDTX CDTX CDTX CDTX CDTX CDTX CDTX CDTX CDTX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-07 2024-08-13 2024-05-15 2024-04-22 2023-11-02 2023-08-03 2023-05-11 2023-03-23 2022-11-03
acceptedDate 2024-11-07 16:08:31 2024-08-13 16:15:14 2024-05-15 16:09:06 2024-04-22 16:56:44 2023-11-02 16:05:17 2023-08-03 16:01:05 2023-05-11 16:12:08 2023-03-23 07:00:50 2022-11-03 17:27:10
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 0 302 000 8M 18M 13M 8M 26M 10M 41M
costOfRevenue 0 57 000 2M 1M 387 000 401 000 0 0 0
grossProfit 0 245 000 7M 16M 12M 7M 26M 10M 41M
grossProfitRatio 0 0.811 0.815 0.935 0.97 0.947 1 1 1
researchAndDevelopmentExpenses 12M 7M 12M 15M 17M 17M 19M 20M 20M
generalAndAdministrativeExpenses 0 5M 6M 7M 4M 3M 4M 3M 6M
sellingAndMarketingExpenses 0 -57 000 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 5M 5M 6M 7M 4M 3M 4M 3M 6M
otherExpenses 0 85M 0 0 0 0 0 0 0
operatingExpenses 17M 11M 18M 23M 21M 20M 23M 23M 26M
costAndExpenses 17M 11M 19M 24M 21M 20M 23M 23M 26M
interestIncome 2M 0 365 000 527 000 613 000 623 000 232 000 0 0
interestExpense 0 0 0 0 0 623 000 232 000 136 000 55 000
depreciationAndAmortization 61 000 57 000 56 000 39 000 22 000 -263 000 320 000 315 000 310 000
ebitda -17M -11M -11M -6M -9M -13M 3M -13M 15M
ebitdaratio 0 -36.57 -1.263 -0.343 -0.673 -1.685 0.115 -1.298 0.374
operatingIncome -17M -11M -11M -6M -9M -13M 3M -13M 15M
operatingIncomeRatio 0 -36.758 -1.263 -0.345 -0.673 -1.685 0.115 -1.298 0.366
totalOtherIncomeExpensesNet 2M 2M 365 000 527 000 613 000 623 000 232 000 162 000 55 000
incomeBeforeTax -16M -94M -10M -6M -8M -12M 3M -13M 15M
incomeBeforeTaxRatio 0 -311.954 -1.22 -0.315 -0.624 -1.603 0.123 -1.282 0.368
incomeTaxExpense 0 -5M -56 000 64 000 -230 000 149 000 213 000 272 000 -110 000
netIncome -16M -89M -10M -6M -8M -12M 3M -13M 15M
netIncomeRatio 0 -296.06 -1.22 -0.319 -0.643 -1.623 0.123 -1.309 0.368
eps -2.38 -19.59 -2.28 -1.25 -0.091 -0.14 0.03 -0.19 0.17
epsdiluted -2.38 -19.59 -2.28 -1.24 -0.091 -0.14 0.03 -0.19 0.17
weightedAverageShsOut 7M 5M 5M 4M 90M 90M 79M 72M 70M
weightedAverageShsOutDil 7M 5M 5M 5M 90M 90M 101M 72M 89M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CDTX CDTX CDTX CDTX CDTX CDTX CDTX CDTX CDTX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-07 2024-08-13 2024-05-15 2024-04-22 2023-11-02 2023-08-03 2023-05-11 2023-03-23 2022-11-03
acceptedDate 2024-11-07 16:08:31 2024-08-13 16:15:14 2024-05-15 16:09:06 2024-04-22 16:56:44 2023-11-02 16:05:17 2023-08-03 16:01:05 2023-05-11 16:12:08 2023-03-23 07:00:50 2022-11-03 17:27:10
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 127M 164M 29M 36M 49M 50M 48M 33M 53M
shortTermInvestments 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 127M 164M 29M 36M 49M 50M 48M 33M 53M
netReceivables 2M 2M 7M 16M 3M 5M 26M 6M 5M
inventory 0 0 7M 6M 2M 2M 0 0 0
otherCurrentAssets 28M 2M 3M 3M 4M 4M 6M 7M 6M
totalCurrentAssets 157M 169M 47M 61M 58M 62M 79M 45M 64M
propertyPlantEquipmentNet 4M 5M 5M 5M 5M 5M 1M 1M 2M
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 2M 0 0 0 0 0
otherNonCurrentAssets 1M 104 000 986 999 1M 1M 1M 1M 1M 1M
totalNonCurrentAssets 6M 5M 6M 8M 6M 6M 2M 2M 3M
otherAssets 0 0 1 0 0 0 0 0 0
totalAssets 162M 173M 53M 69M 63M 68M 82M 48M 67M
accountPayables 3M 2M 5M 4M 4M 2M 4M 1M 4M
shortTermDebt 2M 3M 1M 1M 1M 942 000 1M 1M 1M
taxPayables 26M 26M 21M 18M 0 0 0 0 0
deferredRevenue 0 0 24M 25M 15M 15M 16M 15M 15M
otherCurrentLiabilities 14M 8M 35M 37M 16M 14M 15M 13M 12M
totalCurrentLiabilities 44M 40M 65M 67M 36M 31M 36M 30M 33M
longTermDebt 2M 3M 3M 4M 3M 4M 0 0 344 000
deferredRevenueNonCurrent 0 0 2M 4M 17M 18M 19M 21M 24M
deferredTaxLiabilitiesNonCurrent 0 0 -2M 2M -17M -18M 0 0 0
otherNonCurrentLiabilities 0 0 2M -1 17M 18M 0 0 4M
totalNonCurrentLiabilities 2M 3M 5M 9M 20M 21M 19M 21M 25M
otherLiabilities 0 1 1 1 0 0 0 0 0
capitalLeaseObligations 4M 4M 3M 4M 4M 5M 1M 1M 2M
totalLiabilities 47M 42M 70M 77M 55M 53M 55M 50M 58M
preferredStock 0 1 0 0 0 0 0 0 0
commonStock 1000 1000 1000 9000 9000 9000 9000 7000 7000
retainedEarnings -559M -543M -452M -441M -424M -416M -404M -407M -394M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 -0 0 0 0
othertotalStockholdersEquity 675M 674M 434M 433M 432M 432M 431M 404M 403M
totalStockholdersEquity 116M 131M -18M -8M 8M 15M 27M -3M 9M
totalEquity 116M 131M -18M -8M 8M 15M 27M -3M 9M
totalLiabilitiesAndStockholdersEquity 162M 173M 53M 69M 63M 68M 82M 48M 67M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 162M 173M 53M 69M 63M 68M 82M 48M 67M
totalInvestments 0 0 0 0 0 0 0 0 0
totalDebt 4M 4M 5M 5M 4M 5M 1M 1M 2M
netDebt -123M -160M -24M -31M -44M -46M -47M -31M -51M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CDTX CDTX CDTX CDTX CDTX CDTX CDTX CDTX CDTX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-07 2024-08-13 2024-05-15 2024-04-22 2023-11-02 2023-08-03 2023-05-11 2023-03-23 2022-11-03
acceptedDate 2024-11-07 16:08:31 2024-08-13 16:15:14 2024-05-15 16:09:06 2024-04-22 16:56:44 2023-11-02 16:05:17 2023-08-03 16:01:05 2023-05-11 16:12:08 2023-03-23 07:00:50 2022-11-03 17:27:10
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -13M -94M -10M -6M -8M -12M 3M -13M 15M
depreciationAndAmortization 61 000 57 000 56 000 39 000 22 000 -263 000 320 000 315 000 310 000
deferredIncomeTax 0 0 0 0 0 0 0 0 0
stockBasedCompensation 751 000 703 000 795 000 830 000 796 000 795 000 640 000 673 000 843 000
changeInWorkingCapital 13M -16M 3M -8M 5M 14M -16M -7M 10M
accountsReceivables 650 000 5M 9M -13M 3M 20M -20M -791 000 -210 000
inventory 0 7M -1M -4M -513 000 -2M 0 0 0
accountsPayables 3M -5M -5M 3M 4M -246 000 3M -2M 0
otherWorkingCapital 9M -23M -331 000 -413 000 -468 000 -4M 1M -4M 10M
otherNonCashItems -38M -1M -2M 16M 270 000 229 000 475 000 -2M 2M
netCashProvidedByOperatingActivities -37M -104M -7M -13M -2M 3M -11M -21M 28M
investmentsInPropertyPlantAndEquipment -106 000 0 -23 000 -178 000 -126 000 -107 000 -94 000 -9000 -9000
acquisitionsNet 0 0 0 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0
otherInvestingActivites 0 0 0 0 0 0 0 0 0
netCashUsedForInvestingActivites -106 000 0 -23 000 -178 000 -126 000 -107 000 -94 000 -9000 -9000
debtRepayment -75 000 -75 000 -50 000 0 0 0 0 -3M -371 000
commonStockIssued -107 000 239M -4000 8000 9M -261 000 26M 664 000 1M
commonStockRepurchased 0 0 -39 000 0 63 000 161M 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 4000 -39 000 8000 -9M -161M 14 000 3M -720 000
netCashUsedProvidedByFinancingActivities -182 000 239M -93 000 8000 9M -261 000 26M 664 000 107 000
effectOfForexChangesOnCash 0 0 0 0 6M 0 0 0 0
netChangeInCash -37M 135M -7M -13M -2M 2M 15M -20M 28M
cashAtEndOfPeriod 127M 164M 29M 36M 49M 50M 48M 33M 53M
cashAtBeginningOfPeriod 164M 29M 36M 49M 50M 48M 33M 53M 25M
operatingCashFlow -37M -104M -7M -13M -2M 3M -11M -21M 28M
capitalExpenditure -106 000 0 -23 000 -178 000 -126 000 -107 000 -94 000 -9000 -9000
freeCashFlow -37M -104M -7M -13M -2M 3M -11M -21M 28M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-08-13 20:29 ET
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
2024-07-03 17:05 ET
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-05-30 12:00 ET
Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference
2024-05-15 20:20 ET
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
2024-05-15 20:01 ET
Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules
2024-04-26 12:00 ET
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
2024-04-24 20:05 ET
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million
2024-04-24 20:01 ET
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
2024-04-22 21:10 ET
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
2024-04-22 21:06 ET
Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice
2024-04-22 12:49 ET
Cidara Therapeutics Announces Reverse Stock Split
2024-04-05 19:00 ET
Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
2024-03-06 13:00 ET
Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024
2024-02-12 13:00 ET
Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO
2024-02-12 13:00 ET
Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO
2024-01-29 21:30 ET
Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults
2023-12-22 12:30 ET
Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults
2023-12-07 13:00 ET
Cidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress
2023-12-06 13:00 ET
Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China
2023-12-05 14:00 ET
Melinta Therapeutics & Cidara Therapeutics Announce Publication of Pooled Data from Phase 3 Pivotal ReSTORE Trial & Phase 2 STRIVE Trial of REZZAYO® (rezafungin for injection) for the Treatment of Candidemia & Invasive Candidiasis in The Lancet ID
2023-11-30 13:00 ET
Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress
2023-11-20 13:00 ET
Cidara Therapeutics Named as a San Diego Metro Area Top Workplace
2023-11-03 16:00 ET
Cidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC’s 38ᵗʰ Annual Meeting
2023-11-02 20:15 ET
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
2023-10-13 14:34 ET
Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1)
2023-10-13 14:21 ET
Mundipharma and Cidara Therapeutics receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults¹
2023-10-11 12:30 ET
Cidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023
2023-09-29 20:51 ET
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-09-27 12:00 ET
Cidara Therapeutics to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023
2023-09-07 12:00 ET
Cidara Therapeutics to Host Virtual Research & Development Day on its Cloudbreak® Development Pipeline on September 21, 2023
2023-09-06 20:05 ET
Cidara to Present at the 25th Annual H.C. Wainwright Global Investment Conference
2023-09-06 12:00 ET
Cidara Therapeutics Announces Janssen’s Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza
2023-08-16 12:00 ET
Cidara Therapeutics Announces Appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & Development
2023-08-03 20:08 ET
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
2023-07-31 20:30 ET
Cidara Therapeutics Provides Update on REZZAYO™ (rezafungin for injection)
2023-07-20 21:00 ET
Cidara Therapeutics Provides Update on Status of Ongoing CD388 Influenza Program
2023-06-26 12:00 ET
Cidara Therapeutics Added to Russell Microcap® Index
2023-06-22 12:00 ET
Cidara Therapeutics Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B
2023-06-20 13:55 ET
Cidara Therapeutics to Present Ongoing Development of Drug-Fc Conjugates (DFC) Including CD73-Targeting DFC From Its Cloudbreak® Platform at Adenosine-Pathway Targeted Cancer Immunotherapy Summit
2023-06-13 12:00 ET
Cidara Therapeutics to Present at Adenosine Pathway Targeted Cancer Immunotherapy Summit
2023-05-11 20:37 ET
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
2023-05-03 20:30 ET
Cidara Therapeutics Presents New Preclinical Data on Novel Drug-Fc Conjugate CD388 at the 7th International Society for Influenza and Other Respiratory Virus Diseases Conference
2023-04-24 12:00 ET
Cidara Therapeutics Receives $20 Million Milestone Payment Following FDA Approval of REZZAYO™
2023-03-31 12:00 ET
Cidara Therapeutics to Participate in Upcoming Investor Conferences
2023-03-23 11:12 ET
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
2023-03-22 21:26 ET
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis
2023-03-22 21:23 ET
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis
2023-03-07 21:15 ET
Cidara Therapeutics Presents Preclinical Data on CD73-Targeting Drug-Fc Conjugate at the 2023 ESMO Targeted Anticancer Therapies Congress
2023-03-07 21:01 ET
Cidara Therapeutics Announces Closing of Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares in Public Offering of Common Stock
2023-03-03 14:14 ET
Cidara Therapeutics Announces Pricing of Public Offerings of Common Stock and Preferred Stock
2023-03-02 21:14 ET
Cidara Therapeutics Announces Underwritten Public Offerings of Common Stock and Preferred Stock
2023-03-01 12:00 ET
Cidara Therapeutics Announces Promising Interim Phase 2a Data Assessing the Safety and Efficacy of a Single Dose of CD388 in an Influenza Challenge Model
2023-02-28 13:00 ET
Cidara to Present at ESMO Targeted Anticancer Therapies Congress
2023-02-14 13:00 ET
Cidara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
2023-02-01 13:00 ET
Cidara Therapeutics and WuXi XDC Expand Collaboration for IND-enabling CMC Development to Advance Cidara’s CD73 Oncology DFC Program
2023-01-25 16:02 ET
Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
2023-01-25 12:00 ET
Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
2023-01-04 13:00 ET
Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from its Cloudbreak® Platform
2022-12-01 13:00 ET
Cidara Therapeutics Announces Issuance of First U.S. Patent for CD388
2022-11-29 13:00 ET
Cidara Therapeutics Announces Two Leading Independent Proxy Advisory Firms Recommend Stockholders Vote “FOR” Proposed Reverse Stock Split
2022-11-28 13:00 ET
Cidara Therapeutics and Melinta Therapeutics Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet
2022-11-23 13:00 ET
Cidara Therapeutics to Participate in the World Antiviral Congress 2022
2022-11-08 13:00 ET
Cidara Therapeutics to Present at the Stifel Healthcare Conference
2022-11-03 21:47 ET
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
2022-10-17 12:00 ET
Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2022
2022-10-04 12:00 ET
Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma
2022-09-20 20:05 ET
Cidara Therapeutics Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
2022-09-13 12:00 ET
Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Evaluate CD388 for Universal Prevention of Influenza
2022-09-06 12:00 ET
Cidara Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference
2022-08-09 21:16 ET
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
2022-07-27 12:00 ET
Cidara Therapeutics Submits NDA for Rezafungin and Announces License Agreement with Melinta Therapeutics for Commercialization of Rezafungin in the U.S.
2022-06-27 12:00 ET
Cidara Therapeutics to Host Research and Development Day
2022-05-11 20:13 ET
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
2022-04-25 11:00 ET
Mundipharma and Cidara Therapeutics Announce First Presentation of Results from Global Phase 3 ReSTORE Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrating its Positive Efficacy and Safety Profile
2022-04-14 12:00 ET
Cidara Therapeutics and Mundipharma to Present Results from Global Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and/or Invasive Candidiasis at ECCMID 2022
2022-03-31 12:00 ET
Cidara Therapeutics Announces the Completion of Dosing the First Cohort of Healthy Volunteers in the Phase 1 Trial of CD388 in Development for Universal Prevention and Treatment of Seasonal and Pandemic Influenza
2022-03-07 22:41 ET
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
2022-03-03 12:11 ET
Rezafungin Awarded Promising Innovation Medicine (PIM) Designation by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Invasive Candidiasis
2022-02-14 13:00 ET
Cidara Therapeutics Announces FDA Acceptance of its Investigational New Drug Application for CD388 for Universal Prevention and Treatment of Influenza
2022-01-06 13:00 ET
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-12-14 12:30 ET
Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
2021-12-14 12:00 ET
Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
2021-11-22 13:00 ET
Cidara Therapeutics Named A San Diego Metro Area Top Workplace For The Fifth Consecutive Year
2021-11-10 21:05 ET
Cidara Provides Corporate Update and Reports Third Quarter 2021 Financial Results
2021-10-13 20:01 ET
Cidara Therapeutics Announces Closing of Concurrent Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock
2021-10-08 13:12 ET
Cidara Therapeutics Announces Pricing of Concurrent Public Offerings of Common Stock and Preferred Stock
2021-10-07 20:01 ET
Cidara Therapeutics Announces Commencement of Concurrent Public Offerings of Common Stock and Preferred Stock
2021-10-01 20:11 ET
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-09-29 12:00 ET
Cidara Therapeutics to Present New Data for Rezafungin at TIMM Congress
2021-09-27 12:00 ET
Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2021
2021-09-07 12:00 ET
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
2021-09-02 12:00 ET
Cidara Therapeutics to Host Research and Development Day
2021-09-01 12:00 ET
Cidara Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Financial Officer and Chief Business Officer, and Shane Ward as Chief Legal Officer and Corporate Secretary
2021-08-17 12:00 ET
Cidara Therapeutics and Mundipharma Announce Completion of Enrollment in the Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
2021-08-12 20:43 ET
Cidara Provides Corporate Update and Reports Second Quarter 2021 Financial Results
2021-08-05 12:00 ET
Cidara Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
2021-07-27 12:00 ET
Cidara Therapeutics to Present New Data for Rezafungin at the International Society for Human and Animal Mycology (ISHAM) Asia Congress
2021-07-12 12:00 ET
Cidara Therapeutics Presents New Analyses from Multiple Rezafungin Studies at ECCMID 2021
2021-07-07 12:00 ET
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-07-01 20:01 ET
Cidara Therapeutics Provides Leadership Update
2021-06-30 12:00 ET
Cidara Therapeutics to Present New Analyses for Rezafungin at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
2021-06-14 12:00 ET
Cidara Therapeutics to Participate in the Raymond James Human Health Innovation Conference
2021-06-08 15:18 ET
Crestone Joins Antimicrobials Working Group
2021-06-02 12:00 ET
Cidara to Present at Mycology 2021 Conference
2021-05-13 20:29 ET
Cidara Provides Corporate Update and Reports First Quarter 2021 Financial Results
2021-04-07 12:00 ET
Cidara Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
2021-04-05 11:00 ET
Cidara Therapeutics Announces Agreement with Janssen to Develop and Commercialize AVCs for the Prevention and Treatment of Influenza
2021-04-01 12:00 ET
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-03-03 13:00 ET
Cidara Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
2021-02-25 21:47 ET
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
2021-02-17 15:04 ET
UTILITY Therapeutics Joins Antimicrobials Working Group
2021-02-17 13:00 ET
Cidara Therapeutics Announces New Data for Rezafungin at the 21st ICHS Symposium
2021-02-11 13:00 ET
Cidara Therapeutics to Present New Data for Rezafungin and Influenza AVCs at the 21st ICHS Symposium
2021-01-25 13:00 ET
Cidara Therapeutics Announces Key Additions to its Board of Directors
2021-01-05 21:59 ET
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2020-12-15 13:00 ET
Cidara Therapeutics Appoints Biotechnology Industry Veteran Christopher Kurtz As Executive Vice President of Technical Operations
2020-12-01 13:00 ET
Cidara Therapeutics to Present Preclinical Data for Influenza AVCs at the 7th ESWI Influenza Conference
2020-11-30 13:00 ET
Cidara Therapeutics to Present New Clinical Data for Rezafungin at ESICM LIVES 2020
2020-11-16 13:00 ET
Cidara Therapeutics Named a San Diego Metro Area Top Workplace for the Fourth Consecutive Year
2020-11-11 21:05 ET
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
2020-11-05 21:24 ET
Cidara Provides Corporate Update and Reports Third Quarter 2020 Financial Results
2020-10-21 12:00 ET
Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs at IDWeek 2020
2020-10-13 12:00 ET
Cidara Therapeutics to Present at the 2020 American College of Clinical Pharmacy (ACCP) Annual Meeting
2020-09-14 12:00 ET
Cidara Therapeutics to Present New Clinical and Preclinical Data for Rezafungin and Influenza AVCs at IDWeek 2020
2020-09-02 12:00 ET
Cidara Therapeutics to Participate in Upcoming Investor Conferences
2020-08-13 20:48 ET
Cidara Provides Corporate Update and Reports Second Quarter 2020 Financial Results
2020-08-04 12:00 ET
Cidara Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
2020-07-27 12:00 ET
Cidara Therapeutics Announces Formation of Scientific Advisory Board
2020-07-17 12:00 ET
Cidara Therapeutics to Participate in B. Riley Virtual Summer Series Panel on Antiviral Therapeutics
2020-06-29 12:00 ET
Cidara Therapeutics Added to Russell 3000® Index
2020-06-23 12:00 ET
Cidara Therapeutics to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19
2020-06-11 12:00 ET
Cidara Therapeutics to Present at the Raymond James Human Health Innovations Conference
2020-05-20 12:45 ET
Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation
2020-05-13 20:52 ET
Cidara Provides Corporate Update and Reports First Quarter 2020 Financial Results
2020-05-05 20:30 ET
Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs from the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
2020-04-28 12:00 ET
Cidara Therapeutics to Participate in Antifungal and COVID-19 Therapeutics Panels at Maxim Group’s Infectious Disease Virtual Conference
2020-04-07 12:00 ET
Cidara Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
2020-03-04 10:55 ET
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results
2020-02-18 13:00 ET
Cidara Therapeutics to Present at Transplantation & Cellular Therapy (TCT) and Mycology 2020 Medical Conferences
2020-02-12 22:30 ET
Cidara Therapeutics Announces Closing of Rights Offering
2020-01-22 12:55 ET
Cidara Therapeutics Announces Commencement of Rights Offering
2020-01-10 13:00 ET
Cidara Therapeutics Announces Proposed Rights Offering
2019-12-03 13:00 ET
Cidara Therapeutics to Present at Two Upcoming Medical Conferences
2019-11-18 13:00 ET
Cidara Therapeutics Named a San Diego Metro Area Top Workplace for the Third Consecutive Year
2019-11-08 02:17 ET
Cidara Provides Corporate Update and Reports Third Quarter 2019 Financial Results
2019-11-05 13:00 ET
Cidara Therapeutics Hosting Key Opinion Leader Meeting on Rezafungin and Cloudbreak Programs
2019-10-03 14:22 ET
Cidara Therapeutics to Present New Clinical and Preclinical Data at Two Upcoming Medical Conferences
2019-10-01 14:07 ET
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019
2019-09-16 20:05 ET
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
2019-09-03 13:31 ET
Thinking about buying stock in Cidara Therapeutics, Canopy Growth, Generac, Lowe's, or Medicines Co?
2019-07-01 13:13 ET
X-Biotix Therapeutics Joins Antimicrobials Working Group
2019-06-20 15:13 ET
Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019
2019-06-07 13:27 ET
Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections
2019-04-12 14:08 ET
Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
2019-04-03 20:04 ET
Cidara Therapeutics to Present at the 18th Annual Needham Healthcare Conference
2019-02-28 21:24 ET
Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2018 Financial Results

SEC forms

Show financial reports only

SEC form 8
2025-06-25 20:39 ET
Cidara Therapeutics published news for 2025 q1
SEC form 8
2025-06-25 20:39 ET
Cidara Therapeutics published news for 2025 q1
SEC form 8
2025-06-25 20:39 ET
Cidara Therapeutics published news for 2025 q1
SEC form 8
2025-06-25 20:39 ET
Cidara Therapeutics published news for 2025 q1
SEC form 8
2025-06-25 20:39 ET
Cidara Therapeutics published news for 2025 q1
SEC form 8
2025-06-23 11:05 ET
Cidara Therapeutics published news for 2025 q1
SEC form 8
2025-06-23 11:05 ET
Cidara Therapeutics published news for 2025 q1
SEC form 10
2025-05-08 20:47 ET
Cidara Therapeutics reported for 2025 q1
SEC form 10
2025-05-08 00:00 ET
Cidara Therapeutics reported for 2025 q1
SEC form 8
2025-05-08 00:00 ET
Cidara Therapeutics published news for 2025 q1
SEC form 8
2025-05-08 00:00 ET
Cidara Therapeutics published news for 2025 q1
SEC form 10
2025-03-06 21:25 ET
Cidara Therapeutics reported for 2024 q4
SEC form 10
2025-03-06 00:00 ET
Cidara Therapeutics reported for 2024 q4
SEC form 8
2025-03-06 00:00 ET
Cidara Therapeutics published news for 2024 q4
SEC form 8
2025-03-06 00:00 ET
Cidara Therapeutics published news for 2024 q4
SEC form 8
2024-11-07 16:13 ET
Cidara Therapeutics published news for 2024 q3
SEC form 8
2024-11-07 16:13 ET
Cidara Therapeutics published news for 2024 q3
SEC form 10
2024-11-07 16:08 ET
Cidara Therapeutics published news for 2024 q3
SEC form 10
2024-08-13 16:15 ET
Cidara Therapeutics published news for 2024 q2
SEC form 10
2024-08-13 00:00 ET
Cidara Therapeutics published news for 2024 q2
SEC form 8
2024-08-13 00:00 ET
Cidara Therapeutics published news for 2024 q2
SEC form 8
2024-08-13 00:00 ET
Cidara Therapeutics reported for 2024 q2
SEC form 8
2024-05-15 16:22 ET
Cidara Therapeutics published news for 2024 q1
SEC form 8
2024-05-15 16:22 ET
Cidara Therapeutics reported for 2024 q1
SEC form 10
2024-05-15 16:09 ET
Cidara Therapeutics reported for 2024 q1
SEC form 10
2024-05-15 00:00 ET
Cidara Therapeutics reported for 2024 q1
SEC form 10
2024-04-22 16:56 ET
Cidara Therapeutics published news for 2023 q4
SEC form 10
2024-04-22 00:00 ET
Cidara Therapeutics published news for 2023 q4
SEC form 8
2024-04-22 00:00 ET
Cidara Therapeutics published news for 2024 q1
SEC form 8
2024-04-22 00:00 ET
Cidara Therapeutics published news for 2024 q1
SEC form 8
2024-04-22 00:00 ET
Cidara Therapeutics published news for 2024 q1
SEC form 10
2023-11-02 16:05 ET
Cidara Therapeutics reported for 2023 q3
SEC form 10
2023-11-02 00:00 ET
Cidara Therapeutics reported for 2023 q3
SEC form 8
2023-11-02 00:00 ET
Cidara Therapeutics reported for 2023 q3
SEC form 6
2023-08-03 16:03 ET
Cidara Therapeutics reported for 2023 q2
SEC form 10
2023-08-03 16:01 ET
Cidara Therapeutics reported for 2023 q2
SEC form 10
2023-08-03 00:00 ET
Cidara Therapeutics reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Cidara Therapeutics reported for 2023 q2
SEC form 6
2023-06-23 16:07 ET
Cidara Therapeutics published news for 2023 q1
SEC form 6
2023-05-11 16:16 ET
Cidara Therapeutics reported for 2023 q1
SEC form 10
2023-05-11 16:12 ET
Cidara Therapeutics reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
Cidara Therapeutics reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
Cidara Therapeutics reported for 2023 q1
SEC form 6
2023-04-27 16:40 ET
Cidara Therapeutics published news for 2023 q1
SEC form 6
2023-03-29 17:26 ET
Cidara Therapeutics published news for 2022 q4
SEC form 6
2023-03-23 07:05 ET
Cidara Therapeutics reported for 2022 q4
SEC form 10
2023-03-23 07:00 ET
Cidara Therapeutics reported for 2022 q4
SEC form 10
2023-03-23 00:00 ET
Cidara Therapeutics reported for 2022 q4
SEC form 8
2023-03-23 00:00 ET
Cidara Therapeutics reported for 2022 q4
SEC form 6
2023-03-13 21:21 ET
Cidara Therapeutics published news for 2022 q4
SEC form 6
2023-03-13 21:21 ET
Cidara Therapeutics published news for 2022 q4
SEC form 6
2023-03-13 21:20 ET
Cidara Therapeutics published news for 2022 q4
SEC form 6
2023-03-13 21:19 ET
Cidara Therapeutics published news for 2022 q4
SEC form 6
2023-03-06 16:23 ET
Cidara Therapeutics published news for 2022 q4
SEC form 6
2023-03-02 16:21 ET
Cidara Therapeutics published news for 2022 q4
SEC form 8
2023-03-02 00:00 ET
Cidara Therapeutics published news for 2022 q4
SEC form 6
2023-03-01 07:22 ET
Cidara Therapeutics published news for 2022 q4
SEC form 6
2023-02-14 08:05 ET
Cidara Therapeutics published news for 2022 q4
SEC form 6
2023-01-27 16:33 ET
Cidara Therapeutics published news for 2022 q4
SEC form 6
2022-12-16 16:06 ET
Cidara Therapeutics published news for 2022 q3
SEC form 6
2022-11-10 16:06 ET
Cidara Therapeutics published news for 2022 q3
SEC form 6
2022-11-03 17:30 ET
Cidara Therapeutics reported for 2022 q3
SEC form 10
2022-11-03 17:27 ET
Cidara Therapeutics reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Cidara Therapeutics reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Cidara Therapeutics reported for 2022 q3
SEC form 6
2022-10-31 17:28 ET
Cidara Therapeutics published news for 2022 q3
SEC form 6
2022-10-21 17:02 ET
Cidara Therapeutics published news for 2022 q3
SEC form 6
2022-09-19 20:28 ET
Cidara Therapeutics published news for 2022 q2
SEC form 6
2022-09-13 18:51 ET
Cidara Therapeutics published news for 2022 q2
SEC form 6
2022-09-13 18:40 ET
Cidara Therapeutics published news for 2022 q2
SEC form 6
2022-09-08 16:55 ET
Cidara Therapeutics published news for 2022 q2
SEC form 6
2022-09-02 17:14 ET
Cidara Therapeutics published news for 2022 q2
SEC form 6
2022-08-09 17:07 ET
Cidara Therapeutics published news for 2022 q2
SEC form 10
2022-08-09 17:07 ET
Cidara Therapeutics published news for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Cidara Therapeutics reported for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Cidara Therapeutics reported for 2022 q2
SEC form 6
2022-07-27 08:00 ET
Cidara Therapeutics published news for 2022 q2
SEC form 6
2022-07-07 16:07 ET
Cidara Therapeutics published news for 2022 q2
SEC form 6
2022-06-24 16:12 ET
Cidara Therapeutics published news for 2022 q1
SEC form 6
2022-05-11 16:08 ET
Cidara Therapeutics published news for 2022 q1
SEC form 10
2022-05-11 16:06 ET
Cidara Therapeutics published news for 2022 q1
SEC form 10
2022-05-11 00:00 ET
Cidara Therapeutics reported for 2022 q1
SEC form 8
2022-05-11 00:00 ET
Cidara Therapeutics reported for 2022 q1
SEC form 6
2022-04-29 16:33 ET
Cidara Therapeutics published news for 2022 q1
SEC form 6
2022-04-04 16:06 ET
Cidara Therapeutics published news for 2022 q1
SEC form 6
2022-03-07 17:15 ET
Cidara Therapeutics published news for 2021 q4
SEC form 10
2022-03-07 17:12 ET
Cidara Therapeutics published news for 2021 q4
SEC form 10
2022-03-07 00:00 ET
Cidara Therapeutics published news for 2021 q4
SEC form 8
2022-03-07 00:00 ET
Cidara Therapeutics published news for 2021 q4
SEC form 6
2022-03-04 16:29 ET
Cidara Therapeutics published news for 2021 q4
SEC form 6
2021-12-14 07:05 ET
Cidara Therapeutics published news for 2021 q3
SEC form 6
2021-11-10 16:30 ET
Cidara Therapeutics published news for 2021 q3
SEC form 10
2021-11-10 16:29 ET
Cidara Therapeutics published news for 2021 q3
SEC form 10
2021-11-10 00:00 ET
Cidara Therapeutics published news for 2021 q3
SEC form 8
2021-11-10 00:00 ET
Cidara Therapeutics published news for 2021 q3
SEC form 6
2021-10-08 17:19 ET
Cidara Therapeutics published news for 2021 q3
SEC form 6
2021-09-21 16:00 ET
Cidara Therapeutics published news for 2021 q2
SEC form 6
2021-09-01 08:10 ET
Cidara Therapeutics published news for 2021 q2
SEC form 6
2021-08-17 08:31 ET
Cidara Therapeutics published news for 2021 q2
SEC form 6
2021-08-12 16:31 ET
Cidara Therapeutics published news for 2021 q2
SEC form 10
2021-08-12 16:27 ET
Cidara Therapeutics published news for 2021 q2
SEC form 10
2021-08-12 00:00 ET
Cidara Therapeutics published news for 2021 q2
SEC form 8
2021-08-12 00:00 ET
Cidara Therapeutics published news for 2021 q2
SEC form 6
2021-07-20 16:30 ET
Cidara Therapeutics published news for 2021 q2
SEC form 6
2021-07-01 16:11 ET
Cidara Therapeutics published news for 2021 q2
SEC form 6
2021-06-23 19:04 ET
Cidara Therapeutics published news for 2021 q1
SEC form 6
2021-05-17 16:06 ET
Cidara Therapeutics published news for 2021 q1
SEC form 6
2021-05-13 16:15 ET
Cidara Therapeutics published news for 2021 q1
SEC form 10
2021-05-13 16:12 ET
Cidara Therapeutics published news for 2021 q1
SEC form 8
2021-05-13 00:00 ET
Cidara Therapeutics published news for 2021 q1
SEC form 6
2021-04-28 16:07 ET
Cidara Therapeutics published news for 2021 q1
SEC form 6
2021-04-05 18:45 ET
Cidara Therapeutics published news for 2021 q1
SEC form 6
2021-04-05 07:07 ET
Cidara Therapeutics published news for 2021 q1
SEC form 6
2021-02-25 16:40 ET
Cidara Therapeutics published news for 2020 q4
SEC form 10
2021-02-25 16:36 ET
Cidara Therapeutics published news for 2020 q4
SEC form 6
2021-01-25 08:00 ET
Cidara Therapeutics published news for 2020 q4
SEC form 6
2020-12-07 17:13 ET
Cidara Therapeutics published news for 2020 q3
SEC form 6
2020-11-30 16:17 ET
Cidara Therapeutics published news for 2020 q3
SEC form 6
2020-11-05 16:13 ET
Cidara Therapeutics published news for 2020 q3
SEC form 10
2020-11-05 16:09 ET
Cidara Therapeutics published news for 2020 q3